New BPCRS for the BP 2027 edition
Published 22 October 2026
The British Pharmacopoeia team is proud to release the following new BP chemical reference substances (BPCRS) to support new and updated finished product monographs within the BP 2027 edition.
Our new BPCRS can help facilitate the manufacture of drugs used to treat a range of diseases including Parkinson’s, hypertension and inflammatory disorders.
Our portfolio of legally enforceable written standards (monographs) and highly characterised physical standards (BPCRS) continues to grow to support the fight against global diseases. You can visit the 'About Reference Standards' page to learn more about our BPCRS.
Overview of new BPCRS
| Catalogue Number |
Batch Number |
Name | Pack Size | Intended Purpose |
|---|---|---|---|---|
| 1336 | 4291 | Indapamide impurity Standard | 25mg | Peak identity standard |
| 1324 | 4897 | Carbidopa impurity standard | 25mg | Peak identity standard |
| 1325 | 4898 | Carbidopa Impurity 1 | 25mg | Peak identity standard |
| 1326 | 4899 | Tyrosine (Levodopa impurity B) |
25mg | Peak identity standard |
| 1327 | 4900 | 3-Methoxytyrosine (Levodopa impurity C) |
10mg | Peak identity standard |
| 1331 | 4950 | Timolol impurity standard |
25mg | Peak identity standard |
| 1322 | 4894 | Topiramate | 100mg | Quantitative assay standard |
| 1323 | 4896 | Topiramate impurity A | 25mg | Peak identity standard |
| 1329 | 4902 | Ropinirole impurity A | 25mg | Peak identity standard |
| 1330 | 4903 | Ropinirole for peak identification | 10mg | Peak identity standard |
| 1333 | 4912 | Melatonin impurity 1 | 15mg | Peak identity standard |
| 1334 | 4913 | Clobetasol impurity C | 15mg | Peak identity standard |
We have been able to release all new BPCRS ahead of the BP 2027 edition becoming legally effective on 1 January 2027, to enable users to comply with the BP monographs from day
